Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-7548
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSchmitt, Volker H.-
dc.contributor.authorProchaska, Jürgen H.-
dc.contributor.authorFöll, Annegret S.-
dc.contributor.authorSchulz, Andreas-
dc.contributor.authorKeller, Karsten-
dc.contributor.authorHahad, Omar-
dc.contributor.authorKoeck, Thomas-
dc.contributor.authorTröbs, Sven-Oliver-
dc.contributor.authorRapp, Steffen-
dc.contributor.authorBeutel, Manfred-
dc.contributor.authorPfeiffer, Norbert-
dc.contributor.authorStrauch, Konstantin-
dc.contributor.authorLackner, Karl J.-
dc.contributor.authorMünzel, Thomas-
dc.contributor.authorWild, Philipp S.-
dc.date.accessioned2022-08-11T07:16:41Z-
dc.date.available2022-08-11T07:16:41Z-
dc.date.issued2021-
dc.identifier.urihttps://openscience.ub.uni-mainz.de/handle/20.500.12030/7562-
dc.description.abstractUse of galectin-3 for assessing cardiac function in prediabetes and type 2 diabetes mellitus (T2DM) needs to be established. Within the Gutenberg Health Study cohort (N = 15,010, 35–74 years) patient characteristics were investigated regarding galectin-3 levels. Prognostic value of galectin-3 compared to NT-proBNP concerning cardiac function and mortality was assessed in individuals with euglycaemia, prediabetes and T2DM in 5 years follow-up. Higher galectin-3 levels related to older age, female sex and higher prevalence for prediabetes, T2DM, cardiovascular risk factors and comorbidities. Galectin-3 cross-sectionally was related to impaired systolic (β − 0.36, 95% CI − 0.63/− 0.09; P = 0.008) and diastolic function (β 0.014, 95% CI 0.001/0.03; P = 0.031) in T2DM and reduced systolic function in prediabetes (β − 0.34, 95% CI − 0.53/− 0.15; P = 0.00045). Galectin-3 prospectively related to systolic (β − 0.656, 95% CI − 1.07/− 0.24; P = 0.0021) and diastolic dysfunction (β 0.0179, 95% CI 0.0001/0.036; P = 0.049), cardiovascular (hazard ratio per standard deviation of galectin-3 (HRperSD) 1.60, 95% CI 1.39–1.85; P < 0.0001) and all-cause mortality (HRperSD 1.36, 95% CI 1.25–1.47; P < 0.0001) in T2DM. No relationship between galectin-3 and cardiac function was found in euglycaemia, whereas NT-proBNP consistently related to reduced cardiac function. Prospective value of NT-proBNP on cardiovascular and all-cause mortality was higher. NT-proBNP was superior to galectin-3 to assess reduced systolic and diastolic function.en_GB
dc.language.isoengde
dc.rightsCC BY*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subject.ddc610 Medizinde_DE
dc.subject.ddc610 Medical sciencesen_GB
dc.titleGalectin-3 for prediction of cardiac function compared to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitusen_GB
dc.typeZeitschriftenaufsatzde
dc.identifier.doihttp://doi.org/10.25358/openscience-7548-
jgu.type.dinitypearticleen_GB
jgu.type.versionPublished versionde
jgu.type.resourceTextde
jgu.organisation.departmentFB 04 Medizinde
jgu.organisation.number2700-
jgu.organisation.nameJohannes Gutenberg-Universität Mainz-
jgu.rights.accessrightsopenAccess-
jgu.journal.titleScientific reportsde
jgu.journal.volume11de
jgu.pages.alternative19012de
jgu.publisher.year2021-
jgu.publisher.nameMacmillan Publishers Limited, part of Springer Naturede
jgu.publisher.placeLondonde
jgu.publisher.issn2045-2322de
jgu.organisation.placeMainz-
jgu.subject.ddccode610de
jgu.publisher.doi10.1038/s41598-021-98227-xde
jgu.organisation.rorhttps://ror.org/023b0x485-
Appears in collections:JGU-Publikationen

Files in This Item:
  File Description SizeFormat
Thumbnail
galectin3_for_prediction_of_c-20220811091321351.pdf1.97 MBAdobe PDFView/Open